EUVIMEDEUVIMED entdecken
Crossref

Fascicular Substrate Modification to Treat Human Ventricular Fibrillation

Weeranun D Bode, Sanghamitra Mohanty, John D Burkhardt, Prem G Torlapati, Carola Gianni, Vincenzo M La Fazia, Domenico G Della Rocca, Mohamed Bassiouny, G Joseph Gallinghouse, Rodney Horton, Amin Al-Ahmad, Xiao-Dong Zhang und 4 weitere

JACC: Clinical Electrophysiology · 2024

DOI: 10.1016/j.jacep.2024.03.035 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JACC: Clinical Electrophysiology, 2024. Verfasst von Weeranun D Bode und 15 weiteren Autor:innen. Beteiligte Einrichtung: Electrophysiology Section, Division of Cardiology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA. Electronic address: w…. Hauptthemen laut MEDLINE: Ventricular Fibrillation, Catheter Ablation, Purkinje Fibers. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 16 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Purkinje fibers play an important role in initiation and maintenance of ventricular fibrillation (VF) and polymorphic ventricular tachycardia (PMVT). Fascicular substrate modification (FSM) approaches have been suggested to treat recurrent VF in case reports and small case series. OBJECTIVES: The aim of this study was to investigate outcomes of catheter-based FSM to treat VF and PMVT. METHODS: Of 2,212 consecutive patients with ventricular arrhythmia undergoing catheter ablation, 18 (0.81%) underwent FSM of the Purkinje fibers as identified with high-density mapping during sinus rhythm. Fascicular substrate and VF initiation were mapped using a multipolar catheter. The endpoint of the ablation was noninducibility of VF and PMVT. In select patients, remapping revealed elimination of the targeted Purkinje potentials. Demographic, clinical, and follow-up characteristics were prospectively collected in our institutional database. RESULTS: A total of 18 patients (mean age 56 ± 3.8 years, 22% women) were included in the study. Of those, 11 (61.1%) had idiopathic VF, 3 (16.7%) had nonischemic cardiomyopathy, and 4 (22.2%) had mixed cardiomyopathy. The average left ventricular ejection fraction was 42.5%. At least 2 antiarrhythmic drugs had failed preablation. At baseline, all patients had inducible VF or PMVT. At the end of the procedure, no patient demonstrated new evidence of fascicular block or bundle branch block. There were no procedure-related complications. After a median follow-up period of 24 months, 16 patients (88.9%) were arrhythmia free on or off drugs: 11 of 11 patients (100%) with idiopathic VF vs 5 of 7 patients (71.4%) with underlying cardiomyopathy (P = 0.06). CONCLUSIONS: Catheter ablation of human VF and PMVT with FSM is feasible and safe and appears highly effective, with high rates of acute VF noninducibility and long-term freedom from recurrent VF.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ventricular FibrillationCatheter AblationPurkinje FibersHumansFemaleMaleMiddle AgedTachycardia, VentricularTreatment OutcomeAged

Stichwörter der Autor:innen

Purkinje-like potentialscatheter ablationfascicular substrate modificationventricular arrhythmiaventricular fibrillation

Autor:innen und Institutionen

  • Electrophysiology Section, Division of Cardiology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA. Electronic address: weeranun.bode@hcahealthcare.com.
  • Texas Cardiac Arrhythmia Institute, Austin, Texas, USA.
  • Albert Einstein College of Medicine at Montefiore Health System, New York, New York, USA.
  • Cleveland Clinic Foundation, Cleveland, Ohio, USA.

Zitieren

APA

Bode, W. D., Mohanty, S., Burkhardt, J. D., Torlapati, P. G., Gianni, C., La Fazia, V. M., Della Rocca, D. G., Bassiouny, M., Gallinghouse, G. J., Horton, R., Al-Ahmad, A., Zhang, X. D., Zou, F., Di Biase, L., Santangeli, P., & Natale, A. (2024). Fascicular Substrate Modification to Treat Human Ventricular Fibrillation. JACC: Clinical Electrophysiology. https://doi.org/10.1016/j.jacep.2024.03.035

Vancouver

Bode WD, Mohanty S, Burkhardt JD, Torlapati PG, Gianni C, La Fazia VM, et al. Fascicular Substrate Modification to Treat Human Ventricular Fibrillation. JACC: Clinical Electrophysiology. 2024. doi:10.1016/j.jacep.2024.03.035

BibTeX
@article{Bode2024,
  author = {Bode, Weeranun D and Mohanty, Sanghamitra and Burkhardt, John D and Torlapati, Prem G and Gianni, Carola and La Fazia, Vincenzo M and Della Rocca, Domenico G and Bassiouny, Mohamed and Gallinghouse, G Joseph and Horton, Rodney and Al-Ahmad, Amin and Zhang, Xiao-Dong and Zou, Fengwei and Di Biase, Luigi and Santangeli, Pasquale and Natale, Andrea},
  title = {Fascicular Substrate Modification to Treat Human Ventricular Fibrillation},
  journal = {JACC: Clinical Electrophysiology},
  year = {2024},
  doi = {10.1016/j.jacep.2024.03.035}
}
Kostenlos starten →